Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Progressive HNF1A-MODY pathophysiology revealed by a translational mouse model
Isaline Louvet, Ana Acosta-Montalvo, Chiara Saponaro, Maria Moreno-Lopez, Sana Douffi, Abdelkrim El Karchaoui, Gianni Pasquetti, Julien Thevenet, Nathalie Delalleau, Valery Gmyr, Paolo Giacobini, Stéphanie Espiard, Julie Kerr-Conte, François Pattou, Adrian Liston, Caroline Bonner
Isaline Louvet, Ana Acosta-Montalvo, Chiara Saponaro, Maria Moreno-Lopez, Sana Douffi, Abdelkrim El Karchaoui, Gianni Pasquetti, Julien Thevenet, Nathalie Delalleau, Valery Gmyr, Paolo Giacobini, Stéphanie Espiard, Julie Kerr-Conte, François Pattou, Adrian Liston, Caroline Bonner
View: Text | PDF
Research Article Aging Endocrinology Metabolism

Progressive HNF1A-MODY pathophysiology revealed by a translational mouse model

  • Text
  • PDF
Abstract

HNF1A-MODY, the most common monogenic diabetes, exhibits progressive β cell dysfunction, but existing mouse models fail to recapitulate human disease progression, limiting understanding of pathogenic mechanisms. We developed mice with heterozygous deletion of the Hnf1a transactivation domain (Hnf1a+/Δe4-10) to model human HNF1A haploinsufficiency, conducted cross-sectional metabolic characterization, and validated our findings in HNF1A-deficient human islets. Unlike previous models, Hnf1a+/Δe4-10 mice successfully recapitulated temporal HNF1A-MODY progression. Male mice developed sequential pathophysiology: early insulin resistance in young adults (7 weeks), followed by testosterone deficiency and fasting hyperglycemia in adult mice (10 weeks). Glucose intolerance emerged in middle-aged mice (30 weeks), progressing to multi-organ dysfunction in aged mice (44–70 weeks), characterized by elevated hepatic gluconeogenesis, impaired renal glucose handling, and hepatic steatosis/fibrosis. This dual pathophysiology involving β cell dysfunction and peripheral insulin resistance was associated with dysregulated hormone secretion from both α and β cells in aged mice (40–70 weeks). Human islet studies with HNF1A knockdown confirmed translational relevance, demonstrating reduced SGLT2 protein expression and inappropriate glucagon and insulin secretion. This work established a physiologically relevant HNF1A-MODY model, identified early insulin resistance as a key mechanism triggering hormonal dysfunction, and revealed HNF1A’s role in multi-organ pathophysiology beyond traditional β cell dysfunction.

Authors

Isaline Louvet, Ana Acosta-Montalvo, Chiara Saponaro, Maria Moreno-Lopez, Sana Douffi, Abdelkrim El Karchaoui, Gianni Pasquetti, Julien Thevenet, Nathalie Delalleau, Valery Gmyr, Paolo Giacobini, Stéphanie Espiard, Julie Kerr-Conte, François Pattou, Adrian Liston, Caroline Bonner

×

Figure 8

HNF1A knockdown in human islets recapitulates key features of Hnf1a+/Δe4-10 mouse model.

Options: View larger image (or click on image) Download as PowerPoint
HNF1A knockdown in human islets recapitulates key features of Hnf1a+/Δe4...
(A) HNF1A mRNA expression in human islets isolated from lean donors (n = 10), donors with obesity (n = 16), and T2D (n = 10) donors. (B) HNF1A transcript level in human islets over time in culture. (C) Western blot analysis and quantification of HNF1A protein after siRNA knockdown showing 54% reduction. (D) Western blot analysis and quantification of insulin protein after HNF1A knockdown showing 51% reduction. (E) Dynamic insulin secretion during glucose stimulation (3 mmol/L → 15 mmol/L → 3 mmol/L) in control (siCTRL, black) and siHNF1A (green) islets. Right: Quantification of first-phase and second-phase insulin secretion. (F) Western blot analysis and quantification of SGLT2 protein expression after HNF1A knockdown showing 70% reduction. (G) Western blot analysis of proglucagon and glucagon protein in control and HNF1A-deficient islets, with quantification showing 104% increase in glucagon after HNF1A knockdown. (H) Dynamic glucagon secretion in response to varying glucose concentrations (1 mmol/L → 15 mmol/L) with quantification at 1 mmol/L and 15 mmol/L glucose. (I) Static glucagon secretion at 2 mmol/L and 10 mmol/L glucose. Protein levels normalized to β-actin or GAPDH. Data are presented as means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. One-way ANOVA with Tukey’s post hoc test was used for HNF1A mRNA comparisons, while unpaired t tests were used for protein quantifications and hormone secretion comparisons.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts